10-QPeriod: Q2 FY2002

PFIZER INC Quarterly Report for Q2 Ended Jun 30, 2002

Filed August 13, 2002For Securities:PFE

Summary

Pfizer Inc. reported a solid financial performance for the second quarter and first six months of 2002, showcasing revenue growth driven primarily by sales volume in its key pharmaceutical products. The company demonstrated a strong increase in net income and earnings per share compared to the prior year, reflecting robust operational execution and effective cost management, even with increased R&D and SI&A expenses to support its product pipeline and launches. The company's financial strength is further underscored by healthy cash flow from operations and a significant increase in short-term investments. Notably, Pfizer announced a major strategic move with the definitive agreement to merge with Pharmacia Corporation, valued at approximately $60 billion, indicating a strong growth outlook and commitment to expanding its market presence. Additionally, the company continues its aggressive share repurchase program and has strategically reviewed its consumer product businesses, signaling a focus on optimizing its portfolio.

Key Highlights

  • 1Revenues increased by 5.4% to $8.03 billion for the second quarter and 8.2% to $16.45 billion for the first six months of 2002 compared to the prior year periods.
  • 2Net income for the second quarter rose 7% to $1.96 billion, and for the first six months, it increased 4% to $3.92 billion, with diluted EPS growing to $0.32 and $0.62, respectively.
  • 3The pharmaceutical segment remains the primary revenue driver, with key products like Lipitor, Norvasc, and Zoloft showing strong growth.
  • 4Pfizer announced a definitive agreement to merge with Pharmacia Corporation in a stock-for-stock transaction valued at approximately $60 billion, expected to close by year-end 2002.
  • 5The company significantly increased its share-purchase program authorization from $10 billion to $16 billion, demonstrating commitment to returning capital to shareholders.
  • 6Merger-related costs, primarily integration and restructuring charges from the Warner-Lambert acquisition, decreased significantly compared to the prior year.
  • 7The company is exploring strategic options, including potential sales, for its Adams confectionery, Schick-Wilkinson Sword shaving products, and Tetra aquarium businesses.

Frequently Asked Questions

The proposed merger with Pharmacia Corporation, valued at approximately $60 billion, is expected to close by the end of 2002. This strategic combination is anticipated to enhance Pfizer's market position and is a significant factor in the company's long-term growth strategy, although it introduces near-term integration complexities and costs.

Pfizer is actively reviewing its business portfolio. The company has announced plans to explore strategic options, including possible sales, for its Adams confectionery, Schick-Wilkinson Sword shaving products, and Tetra aquarium businesses. This indicates a strategic focus on optimizing resources and concentrating on core pharmaceutical and consumer healthcare segments.

Pfizer's pharmaceutical segment continues to be the main growth engine. Key products such as Lipitor, Norvasc, Zoloft, and Neurontin have shown strong performance. Revenue growth is primarily driven by increased sales volume from these in-line products and revenue generated from product alliances and co-promotion agreements.

Pfizer maintains a strong financial position. Net cash provided by operating activities was $4.13 billion for the first six months of 2002. The company also has substantial cash and short-term investment balances, totaling over $11.6 billion as of June 30, 2002, indicating strong liquidity and financial flexibility.